Ballicules › Drugs › Estradiol
What it is ER-alpha, ER-beta, and GPER agonist; menopausal vasomotor and genitourinary symptoms.
Why this one Transdermal estradiol avoids hepatic first-pass effects, while vaginal forms directly treat genitourinary symptoms.
What limits it Systemic use raises thrombotic and stroke risk; add a progestogen when the uterus is present to protect the endometrium.
FDA-approved for
menopausal symptoms (~1975)
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Estrogens increase risk of endometrial cancer; increased risks of cardiovascular disease, stroke, DVT/PE, breast cancer, and probable dementia (WHI) — not for prevention of cardiovascular disease or dementia.
FDA dosing Population Start Target Max
Moderate-severe vasomotor symptoms / vulvovaginal atrophy of menopause Adults 1-2 mg QD, cyclic (3 wk on, 1 wk off) Lowest effective dose Titrated to symptoms
Female hypoestrogenism (hypogonadism, castration, primary ovarian failure) Adults 1-2 mg QD Lowest effective maintenance dose Titrated to symptoms
Breast cancer palliation (selected metastatic disease) Adults 10 mg TID x >=3 months 10 mg TID 10 mg TID
Advanced androgen-dependent prostate carcinoma (palliation) Adults 1-2 mg TID 1-2 mg TID 1-2 mg TID
Prevention of postmenopausal osteoporosis Adults Lowest effective dose (not determined) Lowest effective dose Lowest effective dose
Renal Undefined
Hepatic Contraindicated in hepatic impairment or disease
Instructions Use lowest effective dose for shortest duration consistent with treatment goals Add a progestin in women with an intact uterus to reduce endometrial cancer risk Reevaluate periodically (e.g., every 3-6 months)
Contraindications Undiagnosed abnormal genital bleeding Known, suspected, or history of breast cancer (except selected metastatic disease) Known or suspected estrogen-dependent neoplasia Active or history of DVT/pulmonary embolism Active or recent (within past year) arterial thromboembolic disease (e.g., stroke, MI) Liver dysfunction or disease Known or suspected pregnancy
Cautions Cardiovascular and thromboembolic events (stroke, MI, DVT/PE) Malignancies (endometrial, breast, ovarian) Gallbladder disease and pancreatitis Hypertriglyceridemia Elevated blood pressure Retinal vascular thrombosis / visual abnormalities Probable dementia (age >=65) Hypocalcemia; aggravation of porphyria, asthma, epilepsy
Adverse reactions Abnormal vaginal bleeding/spotting Breast tenderness/enlargement Nausea, abdominal cramps/bloating Headache/migraine Mood disturbances Thromboembolic events Weight change
Pregnancy Contraindicated; should not be used during pregnancy
Lactation Undefined
⚠ BOXED WARNINGS
Endometrial cancer Cardiovascular disorders Breast cancer Probable dementia
Cost, est. cash $300–$5,000/dose or month
Generic entry Pre-1982
Classes and tags
Clinical profile
Therapeutic safety burden 2 / 4
Overdose danger 1 / 4
Weight-gain liability 0 / 4
Sedation liability 0 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 0 / 4
Embryofetal risk 1 / 4
Legacy pregnancy category X
Defining liability Venous thromboembolism and hormone-related adverse effects; estrogen also lowers lamotrigine exposure.
Mechanism of action: Estradiol ballicule
Open Estradiol in the interactive console ↗
Memory aids: mascots and interaction avatars
“Es-trojan horse”
Open Estradiol in the interactive console ↗